a small-molecule inhibitor
ChemicalBook > CAS DataBase List > Imatinib mesylate

Imatinib mesylate

a small-molecule inhibitor
Imatinib mesylate Structure
Imatinib mesylate
  • CAS No.220127-57-1
  • Chemical Name:Imatinib mesylate
  • CBNumber:CB7173646
  • Molecular Formula:C30H35N7O4S
  • Formula Weight:589.71
  • MOL File:220127-57-1.mol
Imatinib mesylate Property
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordWarning
  • Hazard statements H302
  • Precautionary statements P301+P312+P330
Imatinib mesylate Price More Price(12)
  • Brand: Sigma-Aldrich
  • Product number: SML1027
  • Product name : Imatinib mesylate
  • Purity: ≥98% (HPLC)
  • Packaging: 10mg
  • Price: $35.1
  • Updated: 2020/08/18
  • Buy: Buy
  • Brand: Sigma-Aldrich
  • Product number: SML1027
  • Product name : Imatinib mesylate
  • Purity: ≥98% (HPLC)
  • Packaging: 100mg
  • Price: $120
  • Updated: 2020/08/18
  • Buy: Buy
  • Brand: TCI Chemical
  • Product number: I0936
  • Product name : Imatinib Mesylate
  • Purity: >98.0%(HPLC)
  • Packaging: 100mg
  • Price: $50
  • Updated: 2020/06/24
  • Buy: Buy
  • Brand: TCI Chemical
  • Product number: I0936
  • Product name : Imatinib Mesylate
  • Purity: >98.0%(HPLC)
  • Packaging: 1g
  • Price: $291
  • Updated: 2020/06/24
  • Buy: Buy
  • Brand: Cayman Chemical
  • Product number: 13139
  • Product name : Imatinib (mesylate)
  • Purity: ≥98%
  • Packaging: 25mg
  • Price: $25
  • Updated: 2020/06/24
  • Buy: Buy

Imatinib mesylate Chemical Properties,Usage,Production

  • a small-molecule inhibitor Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.
    As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.
  • Description In May 2001, the FDA approved imatinib as a new cancer drug after a record review time of just 2.5 months. Imatinib was launched as Gleevec in the US for chronic myelogenous leukemia (CML) in blast crisis, accelerated phase or chronic phase after interferon-alpha failure. This compound can be prepared by a four step sequence from a condensation of the 1-(3-pyridyl)ethanone with dimethyl formamide dimethylacetal, followed by successive cyclization with the methyl-nitrophenyl guanidine, hydrogenolysis and condensation with the benzoyl chloride of the methylpiperazine. Imatinib is the first of a new class of anticancer drugs that are specifically designed to target the molecular pathways involved (oncogenic event) in the development of disease. The Brc-Abl oncoprotein is a constitutively active tyrosine kinase that causes CML. Imatinib is a competitive inhibitor of this tyrosine kinase as well as Abl, Kit and the PDGFR kinases It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates and consequently blocks the proliferation of the leukemic cells. Phase II studies demonstrated that in chronic phase CML, over 90% of the patients had their leukocyte counts return to normal and 56% had a major cytogenic response. No phase III data is currently available. It is clear from the evidence available that imatinib has advantages over IFN-alpha, such as reduced toxicity, more rapid hematological response, higher rate of cytogenic response and oral administration. The drug is well tolerated, producing few side effects, classified as grade 1 nausea, muscle cramps, diarrhea, edema and vomiting. Imatinib is metabolized primarily by the CYP3A4 enzyme system and drugs capable of modulating this system would be expected to modify the patient's exposure. Novartis expects to launch imatinib for the treatment of gastrointestinal stromal tumors in 2002.
  • Chemical Properties Off-White Solid
  • Originator Novartis (Switzerland)
  • Uses A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)
  • Uses Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib
  • Uses Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.
  • Uses echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis
  • Definition ChEBI: A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.
  • brand name Gleevec, Glivec
  • General Description Imatinib is available in 100- and 400-mg capsules for oraladministration and is indicated for the treatment of CML,gastrointestinal stromal tumors (GIST) that express Kit andacute lymphoplastic leukemia that is positive for thePhiladelphia chromosome.
    Bioavailability of the agent is nearly 100% by the oralroute. The agent is highly protein bound and metabolized tothe N-desmethyl derivative by CYP3A4-mediated removalof the piperazinyl methyl group. The resulting metabolite issimilar to the parent in activity. Elimination occurs primarilyin the feces, and the terminal half-life is 18 hours forthe parent and 40 hours of the N-desmethyl metabolite.Resistant forms of the TK are known, which have alteredamino acids that prevent binding. In addition, there may beincreased levels of the kinase itself. The drug is also a substratefor Pgp and an additional efflux transporter known asbreast cancer resistance protein (BCRP), both of which removethe drug from the cell. These transporters are also inhibitedby the agent as well. Severe side effects include ascites,neutropenia, thrombocytopenia, skin rash, andpulmonary edema. Less serious side effects include nausea/vomiting, heartburn, and headache but overall, the agentis better tolerated than most other medications used in treatingthe disease.
Imatinib mesylate Preparation Products And Raw materials
Raw materials
Preparation Products
  • Supplier:
    Frapp's ChemicalNFTZ Co., Ltd.
  • Tel:+86 (576) 8169-6106
  • Fax:+86 (576) 8169-6105
  • Email:sales@frappschem.com
  • Country:China
  • ProdList:886
  • Advantage:50
  • Supplier:
    Capot Chemical Co.,Ltd.
  • Tel:+86(0)13336195806 +86-571-85586718
  • Fax:+86-571-85864795
  • Email:sales@capotchem.com
  • Country:China
  • ProdList:19931
  • Advantage:60
  • Supplier:
    Henan Tianfu Chemical Co.,Ltd.
  • Tel:0371-55170693
  • Fax:0371-55170693
  • Email:info@tianfuchem.com
  • Country:CHINA
  • ProdList:22623
  • Advantage:55
  • Supplier:
    Shanghai Time Chemicals CO., Ltd.
  • Tel:+86-021-57951555
  • Fax:+86-021-57951555
  • Email:jack.li@time-chemicals.com
  • Country:CHINA
  • ProdList:1365
  • Advantage:55
  • Supplier:
  • Tel:18371201331
  • Fax:020-81716319
  • Email:Sales@pipitech.com
  • Country:CHINA
  • ProdList:3048
  • Advantage:55
  • Supplier:
    Shanghai Yingrui Biopharma Co., Ltd.
  • Tel:+86-21-33585366 E-mail:sales03@shyrchem.com
  • Fax:+86-21-34979012
  • Email:sales03@shyrchem.com
  • Country:CHINA
  • ProdList:739
  • Advantage:60
Related articles
220127-57-1, Imatinib mesylateRelated Search:
  • 4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate
  • STI-571
  • ImatinibMesylate/Gleevec
  • Imatinib Methanesulfonate, STI-571, CGP-57148B, Glivec,
  • Imatinib mesylate(TINIBS )
  • Imatinib mesylate
  • Imatinib Methanesulphonate Salt
  • N-(4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)-4-((4-Methylpiperazin-1-yl)Methyl)benzaMide Methanesulfonate
  • N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonic acid
  • ST-1571 Mesylate
  • Imatinib mesylate 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate
  • 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide mesylate
  • CGP 57148
  • Genfatinib
  • 220127-57-1
  • Imatinib mesylate, >=99%
  • 4-(4-methylpiperazinomethyl)benzoyl chloride dihydrochloride
  • 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)phenyl]benz
  • Bcr-abl Inhibitor IV, Imatinib
  • Imatinib mesylate(alpha Form)
  • Imatinib (STI-571) Mesylate
  • Imatinib Mesylate 220127-57-1
  • 4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate
  • Imatinib mesylate - CGP 57148B | STI 571 | Gleevec
  • GLIVEC; CGP-57148B; STI-571
  • 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide
  • Imatinib mesylate / 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
  • Gleevec (Imatinib)
  • IMatinib Mesylate(STI-571)
  • Gleevec, Glivec, CGP-57148B, STI-571
  • 4-[(4-Methyl-1-piperazinyl)Methyl]-N-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyriMidinyl]aMino]phenyl]benzaMide Methanesulfonate
  • CGP-57148B
  • 4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
  • Gleevac
  • Gleevec (IMatinib Mesylate)
  • CGP54148B
  • 4-(4-Methylpiperazin-1-ylMethyl)-N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaMino)phenyl]benzaMide Methanesulfonic acid salt
  • Imantinib mesylate
  • N-(4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)-4-(4-Methylpiperazin-1-yl)benzaMide Methanesulfonate
  • tinib Mesylate
  • Imatinib mesylate (Gleevec, Glivec, CGP-57148B, STI-571)
  • Imatinib for system suitability
  • Bcr-abl Inhibitor IV, Imatinib - CAS 220127-57-1 - Calbiochem
  • Imatinib (Glivec)
  • Imatinib for system suitability CRS
  • Imatinib mesilate CRS
  • Imatinib mesylate salt
  • ImatinibMesylate&gt
  • Imatinib Mesylate β form
  • Imatinib mesyL